ClinicalTrials.gg
CompletedNCT00396279Updated Nov 8, 2022Results posted

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

A Phase 2 interventional study of Denosumab and Calcium/Vitamin D in GCT and Giant Cell Tumor of Bone, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2006, registered Nov 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.

02

Conditions studied

  • GCT
  • Giant Cell Tumor of Bone

Keywords

  • Giant Cell Tumor of Bone
03

In context

Giant Cell Tumor of Bone

23 studies on the registry are indexed under Giant Cell Tumor of Bone; 7 are open to participants now.

This study's enrollment of 37 is below the median of 43 across 16 interventional studies indexed under Giant Cell Tumor of Bone.

Browse Giant Cell Tumor of Bone studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults, 18 years and older
  • confirmed and measurable giant cell tumor (GCT)
  • Recurrent GCT confirmed by radiology or unresectable GCT
  • (ECOG) performance status of 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Pateints for whom surgery to the affected limb/area is planned within 27 days after receiving 1st dose of denosumab
  • Radiation to affected region within 28 days before enrollment to study
  • Known diagnosis of osteosarcoma or brown tumor of bone
  • Known history of second within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ
  • Concurrent treatment with bisphosphonates, calcitonin, or interferon.

Other criteria also apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Denosumab

    Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.

    Biological: Denosumab · Dietary Supplement: Calcium/Vitamin D

Interventions

  • BiologicalDenosumab

    Administered by subcutaneous injection

    Also known as: Xgeva®

  • Dietary supplementCalcium/Vitamin D

    Drug pages: Calcium · Vitamin D

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Giant Cell Tumor Response

    A treatment response was defined for participants with tissue samples obtained and measured by histopathology as: • at least 90% elimination of giant cells relative to Baseline, or • complete elimination of giant cells in cases where giant cells represent \< 5% of tumor cells. A response was defined for participants who have only radiographs (histopathology not available) as lack of progression of the target lesion at week 25 by radiographic measurements compared with Baseline. For participants with both a core biopsy and resected tissue obtained, the sample closest to week 25 was used in the analysis.

    Time frame: From enrollment until 25 weeks

Secondary outcomes

  1. Percent Change From Baseline in Urinary N-telopeptide Corrected for Urine Creatinine

    Urinary N-telopeptide (of type 1 collagen) corrected for urine creatinine (uNTX/Cr) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in uNTX/Cr was measured over time.

    Time frame: Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81

  2. Percent Change From Baseline in Serum C-terminus Peptide (of Type 1 Collagen)

    Serum C-terminus peptide (of type 1 collagen; CTX1) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in CTX was measured over time.

    Time frame: Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81

  3. Serum Denosumab Trough Concentrations

    Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA).

    Time frame: Blood samples were collected on Days 1 (baseline), 8, 15 and Weeks 5 (Day 29), 9, 13, 25, and 49.

  4. Number of Participants With Adverse Events (AEs)

    An adverse event is defined as an undesirable medical occurrence (e.g., sign, symptom, or diagnosis) or worsening of a pre-existing medical condition. A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the participant at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) based on the following general guideline: Grade 1: Mild AE Grade 2: Moderate AE Grade 3: Severe AE Grade 4: Life-threatening or disabling AE Grade 5: Death related to AE. AEs were assessed by the Investigator for relatedness to study drug.

    Time frame: From the first dose of study drug until the data cut-off date of April 7 2008; a maximum of 18 months

  5. Number of Participants With Anti-Denosumab Antibodies

    Validated immunoassays were used to test for the presence of anti-denosumab antibodies throughout the study.

    Time frame: From enrollment until the data cut-off date of April 7 2008; a maximum time of 18 months.

07

Results

Posted Mar 5, 2014

Participant flow

First patient enrolled 10 July 2006; Last patient enrolled 25 January 2008. Results data are reported as of the data cut-off date of 07 April 2008.

Participant flow — Overall Study
MilestoneDenosumab
Started37
Completed7
Not completed30
Withdrew: Ongoing in study26
Withdrew: Disease progression2
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Participants With Giant Cell Tumor Response

A treatment response was defined for participants with tissue samples obtained and measured by histopathology as: • at least 90% elimination of giant cells relative to Baseline, or • complete elimination of giant cells in cases where giant cells represent \< 5% of tumor cells. A response was defined for participants who have only radiographs (histopathology not available) as lack of progression of the target lesion at week 25 by radiographic measurements compared with Baseline. For participants with both a core biopsy and resected tissue obtained, the sample closest to week 25 was used in the analysis.

Time frame:
From enrollment until 25 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Giant Cell Tumor Response
percentage of participantsDenosumab
Percentage of Participants With Giant Cell Tumor Response85.7 (69.7 to 95.2)
SecondaryPercent Change From Baseline in Urinary N-telopeptide Corrected for Urine Creatinine

Urinary N-telopeptide (of type 1 collagen) corrected for urine creatinine (uNTX/Cr) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in uNTX/Cr was measured over time.

Time frame:
Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81
Reported as:
Median · percent change
Percent Change From Baseline in Urinary N-telopeptide Corrected for Urine Creatinine
percent changeDenosumab
Week 5 (n=30)-70.9 (-79.6 to -15.0)
Week 9 (n=29)-77.0 (-85.7 to -42.9)
Week 13 (n=27)-60.0 (-84.2 to -36.0)
Week 17 (n=26)-59.5 (-79.3 to -37.1)
Week 21 (n=24)-64.5 (-80.1 to -19.1)
Week 25 (n=20)-56.4 (-76.2 to 3.6)
Week 29 (n=21)-52.8 (-78.4 to -22.8)
Week 33 (n=15)-35.0 (-83.8 to 22.0)
Week 37 (n=13)-71.1 (-83.4 to -41.4)
Week 41 (n=11)-57.3 (-78.1 to -22.4)
Week 45 (n=8)-59.1 (-81.8 to -47.5)
Week 49 (n=7)-59.0 (-74.0 to -0.9)
Week 53 (N=8)-49.0 (-81.5 to -29.3)
Week 57 (n=6)-65.1 (-78.4 to -21.9)
Week 61 (n=3)-59.2 (-92.5 to 23.1)
Week 65 (n=3)-69.2 (-79.6 to 33.2)
Week 69 (n=4)-64.2 (-88.8 to -13.4)
Week 73 (n=1)-47.5 (-47.5 to -47.5)
Week 77 (n=2)-76.8 (-86.8 to -66.7)
Week 81 (n=2)-13.3 (-53.8 to 27.1)
SecondaryPercent Change From Baseline in Serum C-terminus Peptide (of Type 1 Collagen)

Serum C-terminus peptide (of type 1 collagen; CTX1) is a bone turnover marker used to measure the activity of denosumab. Percent change from Baseline in CTX was measured over time.

Time frame:
Baseline and Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, and 81
Reported as:
Median · percent change
Percent Change From Baseline in Serum C-terminus Peptide (of Type 1 Collagen)
percent changeDenosumab
Week 5 (n=33)-78.9 (-85.2 to -71.2)
Week 9 (n=33)-79.8 (-87.9 to -66.1)
Week 13 (n=31)-80.4 (-85.7 to -71.3)
Week 17 (n=28)-82.6 (-85.2 to -70.4)
Week 21 (n=26)-82.0 (-87.0 to -66.4)
Week 25 (n=24)-79.5 (-86.5 to -69.2)
Week 29 (n=21)-82.8 (-85.2 to -60.3)
Week 33 (n=16)-74.8 (-83.2 to -59.0)
Week 37 (n=14)-82.4 (-87.0 to -69.6)
Week 41 (n=10)-86.1 (-89.6 to -58.5)
Week 45 (n=8)-79.6 (-86.4 to -70.0)
Week 49 (n=7)-82.0 (-90.0 to -76.7)
Week 53 (N=8)-87.3 (-89.8 to -84.2)
Week 57 (n=6)-86.2 (-87.7 to -85.2)
Week 61 (n=4)-84.9 (-88.3 to -83.0)
Week 65 (n=3)-83.5 (-87.0 to -77.5)
Week 69 (n=4)-84.2 (-86.9 to -80.0)
Week 73 (n=2)-81.9 (-85.2 to -78.5)
Week 77 (n=2)-84.2 (-87.5 to -80.9)
Week 81 (n=2)-84.9 (-89.6 to -80.3)
SecondarySerum Denosumab Trough Concentrations

Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA).

Time frame:
Blood samples were collected on Days 1 (baseline), 8, 15 and Weeks 5 (Day 29), 9, 13, 25, and 49.
Reported as:
Mean · ng/mL
Serum Denosumab Trough Concentrations
ng/mLDenosumab
Day 1 (n=32)NA ± NA
Day 8 (n=32)19000 ± 24100
Day 15 (n=28)31600 ± 27300
Day 29 (n=33)36400 ± 20600
Week 9 (n=32)27500 ± 17300
Week 13 (n=25)23300 ± 12400
Week 25 (n=23)19900 ± 9700
Week 49 (n=9)21400 ± 8900
SecondaryNumber of Participants With Adverse Events (AEs)

An adverse event is defined as an undesirable medical occurrence (e.g., sign, symptom, or diagnosis) or worsening of a pre-existing medical condition. A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the participant at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) based on the following general guideline: Grade 1: Mild AE Grade 2: Moderate AE Grade 3: Severe AE Grade 4: Life-threatening or disabling AE Grade 5: Death related to AE. AEs were assessed by the Investigator for relatedness to study drug.

Time frame:
From the first dose of study drug until the data cut-off date of April 7 2008; a maximum of 18 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsDenosumab
Any AE33
Serious AE5
Fatal AE1
AE leading to study discontinuation2
AE leading to study drug discontinuation3
CTCAE Grade 3, 4, or 55
Any AE related to study drug10
SecondaryNumber of Participants With Anti-Denosumab Antibodies

Validated immunoassays were used to test for the presence of anti-denosumab antibodies throughout the study.

Time frame:
From enrollment until the data cut-off date of April 7 2008; a maximum time of 18 months.
Reported as:
Number · participants
Number of Participants With Anti-Denosumab Antibodies
participantsDenosumab
Number of Participants With Anti-Denosumab Antibodies0

Adverse events

Collected over up to 1 year 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 120 mg Q4W—5/37 (13.5%)25/37 (67.6%)
Most frequent serious events
Most frequent serious events
EventDenosumab 120 mg Q4W
DyspnoeaRespiratory, thoracic and mediastinal disorders2/37
NauseaGastrointestinal disorders1/37
Lower respiratory tract infectionInfections and infestations1/37
PneumoniaInfections and infestations1/37
Ankle fractureInjury, poisoning and procedural complications1/37
Back painMusculoskeletal and connective tissue disorders1/37
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/37
DepressionPsychiatric disorders1/37
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders1/37
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDenosumab 120 mg Q4W
Pain in extremityMusculoskeletal and connective tissue disorders7/37
Back painMusculoskeletal and connective tissue disorders4/37
HeadacheNervous system disorders4/37
DiarrhoeaGastrointestinal disorders3/37
FatigueGeneral disorders3/37
NasopharyngitisInfections and infestations3/37
ArthralgiaMusculoskeletal and connective tissue disorders3/37
ConstipationGastrointestinal disorders2/37
NauseaGastrointestinal disorders2/37
AstheniaGeneral disorders2/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)Denosumab
Mean33.9 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab
Female20
Male17
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Denosumab
White or Caucasian27
Black or African American2
Hispanic or Latino5
Asian3
Giant Cell Tumor Disease Type
Giant Cell Tumor Disease Type(participants)Denosumab
Primary unresectable13
Recurrent unresectable18
Recurrent resectable6
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Denosumab
0 - Fully Active13
1 - Restricted but ambulatory21
2 - Ambulatory but unable to work1
3 - Limited selfcare, confined to bed >50% daytime0
4 - Completely disabled0
Missing2
Percent of giant cells in tumor on pre-treatment biopsy
Percent of giant cells in tumor on pre-treatment biopsy(percentage of giant cells in tumor)Denosumab
Mean28.7 ± 16.1
Location of target lesion
Location of target lesion(participants)Denosumab
Lower extremities8
Upper extremities5
Pelvis9
Spine3
Pulmonary disease9
Dorsal vertebrae1
Pelvic region1
Missing1
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578. Epub 2012 Jun 18. PubMed 22711702 ↗
  • Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. doi: 10.1016/S1470-2045(10)70010-3. Epub 2010 Feb 10. PubMed 20149736 ↗
  • Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3. PubMed 30231890 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2006 to primary completion in Apr 2008, 20 months.

Results were first posted in Mar 2014, 5 years 10 months after primary completion. A results delay was requested in Jun 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
StartActual
Jul 10, 2006
Primary completionActual
Apr 7, 2008
CompletionActual
Feb 1, 2011
Results delay requested
Jun 10, 2010
Results first posted
Mar 5, 2014
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396279
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 6, 2006
Start date
Jul 10, 2006
Primary completion
Apr 7, 2008
Completion
Feb 1, 2011
Results posted
Mar 5, 2014
Last update
Nov 8, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion